BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 17878404)

  • 41. Sexuality, Menopausal Symptoms, and Quality of Life in Premenopausal Women in the First Year Following Hematopoietic Cell Transplantation.
    Tierney DK; Palesh O; Johnston L
    Oncol Nurs Forum; 2015 Sep; 42(5):488-97. PubMed ID: 26302277
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
    Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
    PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Haploidentical allogeneic hematopoietic stem cell transplantation compared to matched unrelated transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Gu B; Wu X; Chen G; Ma X; Jin Z; Tang X; Han Y; Fu C; Qiu H; Sun A; Wu D
    Leuk Res; 2017 Aug; 59():41-46. PubMed ID: 28549237
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Late Mortality and Causes of Death among Long-Term Survivors after Allogeneic Stem Cell Transplantation.
    Atsuta Y; Hirakawa A; Nakasone H; Kurosawa S; Oshima K; Sakai R; Ohashi K; Takahashi S; Mori T; Ozawa Y; Fukuda T; Kanamori H; Morishima Y; Kato K; Yabe H; Sakamaki H; Taniguchi S; Yamashita T;
    Biol Blood Marrow Transplant; 2016 Sep; 22(9):1702-1709. PubMed ID: 27246369
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Neuropsychologic changes from before transplantation to 1 year in patients receiving myeloablative allogeneic hematopoietic cell transplant.
    Syrjala KL; Dikmen S; Langer SL; Roth-Roemer S; Abrams JR
    Blood; 2004 Nov; 104(10):3386-92. PubMed ID: 15251983
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Survival and Late Effects after Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancy at Less than Three Years of Age.
    Vrooman LM; Millard HR; Brazauskas R; Majhail NS; Battiwalla M; Flowers ME; Savani BN; Akpek G; Aljurf M; Bajwa R; Baker KS; Beitinjaneh A; Bitan M; Buchbinder D; Chow E; Dandoy C; Dietz AC; Diller L; Gale RP; Hashmi SK; Hayashi RJ; Hematti P; Kamble RT; Kasow KA; Kletzel M; Lazarus HM; Malone AK; Marks DI; O'Brien TA; Olsson RF; Ringden O; Seo S; Steinberg A; Yu LC; Warwick A; Shaw B; Duncan C
    Biol Blood Marrow Transplant; 2017 Aug; 23(8):1327-1334. PubMed ID: 28461213
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem Cell Transplantation: An Ancillary Analysis of a Randomized Controlled Trial Comparing Tacrolimus/Sirolimus and Tacrolimus/Methotrexate (Blood and Marrow Transplant Clinical Trials Network/BMT CTN 0402).
    Gooptu M; Kim HT; Howard A; Choi SW; Soiffer RJ; Antin JH; Ritz J; Cutler CS
    Biol Blood Marrow Transplant; 2019 Nov; 25(11):2143-2151. PubMed ID: 31271885
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Outcomes of lung transplantation after allogeneic hematopoietic stem cell transplantation.
    Cheng GS; Edelman JD; Madtes DK; Martin PJ; Flowers ME
    Biol Blood Marrow Transplant; 2014 Aug; 20(8):1169-75. PubMed ID: 24727334
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Impact of Disease Risk and Post Allograft Minimal Residual Disease on Survival.
    Dhakal B; D'Souza A; Martens M; Kapke J; Harrington AM; Pasquini M; Saber W; Drobyski WR; Zhang MJ; Hamadani M; Hari PN
    Clin Lymphoma Myeloma Leuk; 2016 Jul; 16(7):379-86. PubMed ID: 27160644
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sexual functioning in women after surgical treatment for endometrial cancer: a prospective controlled study.
    Aerts L; Enzlin P; Verhaeghe J; Poppe W; Vergote I; Amant F
    J Sex Med; 2015 Jan; 12(1):198-209. PubMed ID: 25402322
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study Results.
    Kebriaei P; Bassett R; Lyons G; Valdez B; Ledesma C; Rondon G; Oran B; Ciurea S; Alousi A; Popat U; Patel K; Ahmed S; Olson A; Bashir Q; Shah N; Jones R; Marin D; Rezvani K; Nieto Y; Khouri I; Qazilbash M; Hosing C; Shpall E; Champlin RE; Andersson BS
    Biol Blood Marrow Transplant; 2017 Feb; 23(2):285-292. PubMed ID: 27816651
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis.
    Ghosh N; Karmali R; Rocha V; Ahn KW; DiGilio A; Hari PN; Bachanova V; Bacher U; Dahi P; de Lima M; D'Souza A; Fenske TS; Ganguly S; Kharfan-Dabaja MA; Prestidge TD; Savani BN; Smith SM; Sureda AM; Waller EK; Jaglowski S; Herrera AF; Armand P; Salit RB; Wagner-Johnston ND; Fuchs E; Bolaños-Meade J; Hamadani M
    J Clin Oncol; 2016 Sep; 34(26):3141-9. PubMed ID: 27269951
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Late side effects unchanged 4-8 years after radiotherapy for prostate carcinoma: a comparison with age-matched controls.
    Fransson P; Widmark A
    Cancer; 1999 Feb; 85(3):678-88. PubMed ID: 10091741
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: retrospective follow-up of an open-label, randomised phase 3 trial.
    Fasslrinner F; Schetelig J; Burchert A; Kramer M; Trenschel R; Hegenbart U; Stadler M; Schäfer-Eckart K; Bätzel M; Eich H; Stuschke M; Engenhart-Cabillic R; Krause M; Dreger P; Neubauer A; Ehninger G; Beelen D; Berdel WE; Siepmann T; Stelljes M; Bornhäuser M
    Lancet Haematol; 2018 Apr; 5(4):e161-e169. PubMed ID: 29550384
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Performance limitations and participation restrictions among childhood cancer survivors treated with hematopoietic stem cell transplantation: the bone marrow transplant survivor study.
    Ness KK; Bhatia S; Baker KS; Francisco L; Carter A; Forman SJ; Robison LL; Rosenthal J; Gurney JG
    Arch Pediatr Adolesc Med; 2005 Aug; 159(8):706-13. PubMed ID: 16061776
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Relative Telomere Length before Hematopoietic Cell Transplantation and Outcome after Unrelated Donor Hematopoietic Cell Transplantation for Acute Leukemia.
    Wang Y; Wang T; Dagnall C; Haagenson M; Spellman SR; Hicks B; Jones K; Lee SJ; Savage SA; Gadalla SM
    Biol Blood Marrow Transplant; 2017 Jul; 23(7):1054-1058. PubMed ID: 28389255
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Long term survival among patients who are disease free at 1-year post allogeneic hematopoietic cell transplantation: a single center analysis of 389 consecutive patients.
    Solh MM; Bashey A; Solomon SR; Morris LE; Zhang X; Brown S; Holland HK
    Bone Marrow Transplant; 2018 May; 53(5):576-583. PubMed ID: 29335633
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Sexual dysfunction is prevalent in female lymphoma survivors after autologous stem-cell transplantation and is associated with younger age, chronic fatigue, and mental distress.
    Bersvendsen HS; Haugnes HS; Dahl AA; Fagerli UM; Fluge Ø; Holte H; Wilsgaard T; Smeland KB; Kiserud CE
    Bone Marrow Transplant; 2021 Apr; 56(4):968-970. PubMed ID: 33139869
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation.
    Gilleece MH; Labopin M; Yakoub-Agha I; Volin L; Socié G; Ljungman P; Huynh A; Deconinck E; Wu D; Bourhis JH; Cahn JY; Polge E; Mohty M; Savani BN; Nagler A
    Am J Hematol; 2018 Sep; 93(9):1142-1152. PubMed ID: 29981272
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Risk factors for invasive fungal disease after allogeneic hematopoietic stem cell transplantation: a single center experience.
    Omer AK; Ziakas PD; Anagnostou T; Coughlin E; Kourkoumpetis T; McAfee SL; Dey BR; Attar E; Chen YB; Spitzer TR; Mylonakis E; Ballen KK
    Biol Blood Marrow Transplant; 2013 Aug; 19(8):1190-6. PubMed ID: 23747459
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.